Sign In
Buy AGRX
$1.51
+0 (+0%)
At Close: Nov 25, 2024
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
09:48am, Thursday, 09'th Feb 2023
TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.
Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference
08:30am, Thursday, 01'st Dec 2022
PRINCETON, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it will participate in the RHK Capital Disruptive Growth
Agile Therapeutics, Inc. (AGRX) Q3 2022 Earnings Call Transcript
06:59pm, Monday, 07'th Nov 2022
Agile Therapeutics, Inc. (NASDAQ:AGRX ) Q3 2022 Results Conference Call November 7, 2022 4:30 PM ET Company Participants Matthew Riley - Head of Investor Relations Alfred Altomari - Chairman and Chief
Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022
08:30am, Wednesday, 26'th Oct 2022
Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET
Agile Therapeutics Announces Reorganization of Leadership Team
08:25pm, Friday, 07'th Oct 2022 GlobeNewswire Inc.
Appointment of Amy Welsh to Chief Commercial Officer Prioritizes Commercial Growth
Agile Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
12:30pm, Tuesday, 06'th Sep 2022 GlobeNewswire Inc.
PRINCETON, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Chairman and Chief Executive Officer Al Altomari and Vice P
Agile Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08:30am, Tuesday, 06'th Sep 2022
PRINCETON, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Chairman and Chief Executive Officer Al Altomari and Vice Pre
These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)
08:22pm, Friday, 02'nd Sep 2022
Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).
Agile Therapeutics (AGRX) Q2 2022 Earnings Call Transcript
01:30am, Friday, 12'th Aug 2022 The Motley Fool
AGRX earnings call for the period ending June 30, 2022.
Agile Therapeutics, Inc. (AGRX) CEO Al Altomari on Q2 2022 Results - Earnings Call Transcript
07:17pm, Thursday, 11'th Aug 2022
Agile Therapeutics, Inc. (NASDAQ:AGRX ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Matt Riley - Head, IR Al Altomari - Chairman and CEO Amy Welsh - VP, Marketing C
Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022
12:05pm, Thursday, 28'th Jul 2022 GlobeNewswire Inc.
Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET
Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022
08:05am, Thursday, 28'th Jul 2022
Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET
Woman-Health Focused Stock Agile Therapeutics Is 'Better Positioned,' Analyst Says While Upgrading Stock
07:47pm, Tuesday, 26'th Jul 2022 Benzinga
Maxim Group upgraded Agile Therapeutics Inc (NASDAQ: AGRX) to Buy from Hold with a price target of $1, saying it should be better positioned to begin to rebound.
Agile recently closed an equity off
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022
02:30pm, Tuesday, 26'th Jul 2022 Benzinga
Upgrades
For Agile Therapeutics Inc (NASDAQ:AGRX), Maxim Group upgraded the previous rating of Hold to Buy. For the first quarter, Agile Therapeutics had an EPS of $3.78, compared to year-ago quarter
Agile Therapeutics Updates Second Quarter 2022 Guidance
12:05pm, Tuesday, 12'th Jul 2022 GlobeNewswire Inc.
Twirla® Demand Guidance (Total Cycles) Expected to be at Midpoint of Guided Range
